Morphic Holding, Inc. MORF
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.86B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -15.53
- Beta
- 1.49
- Short ratio
- 0.37
- Inst. own
- 91.02%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 25, 2024
- 50-d avg
- 45.38
- 200-d avg
- 34.15
- 1y target
- 56.13
Key statistics
- Market cap
- 2.86B
- Enterprise value
- 2.24B
- Trailing P/E
- 0.00
- Forward P/E
- -15.53
- PEG ratio
- 0.00
- Price / book
- 4.62
- EPS (TTM)
- -3.83
- Beta
- 1.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -77.53M
- Total cash
- 628.37M
- Total debt
- 3.32M
- Return on equity
- -26.68%
- Shares outstanding
- 50.22M
- Short % of float
- 7.55%
- 50-day average
- 45.38
- 200-day average
- 34.15
Analyst view
Consensus: hold
- Target (low)
- 40.00
- Target (mean)
- 56.13
- Target (high)
- 64.00
Next earnings
Jul 25, 2024
Expected Jul 25, 2024. Consensus EPS estimate -0.88.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 25, 2024 | Jun 1, 2024 | -0.96 | — | — | — |
| Apr 25, 2024 | Mar 1, 2024 | -0.96 | — | — | — |
| Feb 22, 2024 | Dec 1, 2023 | -0.89 | — | — | — |
| Nov 3, 2023 | Sep 1, 2023 | -0.98 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -0.90 | — | — | — |
| Apr 25, 2023 | Mar 1, 2023 | -0.85 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 27, 2023 | BMO Capital | main | Outperform | Outperform |
| Sep 24, 2023 | Stifel | main | Hold | Hold |
| Sep 24, 2023 | BTIG | down | Buy | Neutral |
| Aug 8, 2023 | Stifel | down | Buy | Hold |
| Jul 20, 2023 | Berenberg | init | — | Buy |
| Apr 25, 2023 | RBC Capital | main | — | Outperform |
About Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- morphictx.com
News
- Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Highs On Monday
- Stocks That Hit 52-Week Highs On Tuesday
- Stocks That Hit 52-Week Highs On Monday
Your note
Sign in to keep a note on MORF — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEVAUL WILLIAM DAVID | General Counsel | Stock Gift | Aug 5, 2024 | 19,587 |
| EDWARDS MARTIN | Director | Purchase | Nov 12, 2023 | 2,376 |
| FARRELL ROBERT E. JR. | Officer | Stock Gift | Aug 1, 2024 | 11,781 |
| LINDE PETER | Officer | Sale | Sep 15, 2021 | 11,272 |
| NASHAT AMIR H. | Director | Sale | May 20, 2021 | 0 |
| ROGERS BRUCE N | President | Sale | Jul 7, 2024 | 149,883 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.34% | 6,873,814 | 394.08M | Jun 29, 2023 |
| EcoR1 Capital, LLC | 8.03% | 3,846,964 | 220.55M | Jun 29, 2023 |
| Blackrock Inc. | 5.74% | 2,748,818 | 157.59M | Jun 29, 2023 |
| Wellington Management Group, LLP | 4.81% | 2,303,835 | 132.08M | Jun 29, 2023 |
| Price (T.Rowe) Associates Inc | 4.57% | 2,192,385 | 125.69M | Jun 29, 2023 |
| Artal Group S.A. | 4.47% | 2,139,995 | 122.69M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 2.67% | 1,280,968 | 70.56M | Aug 30, 2023 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.29% | 1,095,532 | 60.34M | Aug 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.20% | 1,052,396 | 60.33M | Jun 29, 2023 |
| Price (T.Rowe) New Horizons Fund | 1.95% | 936,235 | 53.67M | Jun 29, 2023 |
| Fidelity Select Portfolios - Biotechnology | 1.79% | 857,637 | 47.24M | Aug 30, 2023 |
| iShares Russell 2000 ETF | 1.45% | 694,754 | 38.27M | Aug 30, 2023 |